Congresos 2024
En esta página podrá descargarse la información más relevante de Larotrectinib presentada en los congresos de 2024.
- Outcomes of Larotrectinib compared with real-world data from non-TRK inhibitor therapiesexpand_more
Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study. JCO 42, 3105-3105(2024). DOI:10.1200/JCO.2024.42.16_suppl.3105
- Larotrectinib in TRK fusion Thyroid Carcinomaexpand_more
Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). JCO 42, 6095-6095(2024). DOI:10.1200/JCO.2024.42.16_suppl.6095
- Larotrectinib in TRK fusion Lung Cancerexpand_more
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. JCO 41, 9056-9056(2023). DOI:10.1200/JCO.2023.41.16_suppl.9056
- Larotrectinib in TRK fusion GI Cancerexpand_more
Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer. JCO 42, 109-109(2024). DOI:10.1200/JCO.2024.42.3_suppl.109